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Summary
The present studies have evaluated the effect of age on the induction of syngeneic graft-versus-
host disease (SGVHD) after syngeneic bone marrow transplantation (BMT) and cyclosporine
(CsA) therapy. The results clearly document an inverse correlation of age with the incidence
of SGVHD. Virtually a 100% incidence of SGVHD occurs in Lewis rats when syngeneic BMT
and CsA therapy are started when the animals are 4 wk of age. Thereafter, there is a dramatic
decline in the incidence of SGVHD with the increasing age of the animals. Although the age
of the recipient was important, the most significant effect was the age of the marrow donor .
Marrow from animals 6 mo of age was virtually incapable of eliciting SGVHD after BMT and
CsA therapy. Furthermore, mixing the marrow from mature and immature animals resulted
in a decreased incidence of SGVHD, implicating a regulatory effect present in the marrow from
older rats. This regulatory effect was due to the presence of mature T cells in the marrow from
animals 6 mo of age. Despite the fact that marrow from young animals possesses mature T
lymphocytes, this regulatory activity was absent, suggesting that the host resistance mediated
by T lymphocytes develops as the animal ages. These data further implicate the importance of
a host resistance mechanism in preventing the induction of SGVHD with CsA, which appears
to be mediated by the clonal inactivation of autoreactive cells.
C
yclosporine (CsA)l is a very potent immunosuppressive
agent that has an apparent selective action on T lym-
phocyte-dependent immune responses (1, 2). It has been used
extensively in clinical transplantation to prevent solid organ
allograft rejection and graft-versus-host disease (GVHD) (3,
4). CsA is currently being evaluated as a therapeutic agent
for the treatment ofautoimmune disease, and the results from
these trials appear quite promising (5). Despite its potent im-
munosuppressive activity, CsA therapy after autologous or
syngeneic bone marrow transplantation paradoxically elicits
a T cell-mediated autoimmune syndrome with pathology
identical to GVHD occurring after allogeneic bone marrow
transplantation (BMT) (6-10). Hence, this CsA-induced au-
toimmune syndrome was originally termed syngeneic GVHD
(SGVHD) (6). The immunobiology of SGVHD is complex
and is not completely understood, but it appears to be due
to the uncoupling of normal immunologic homeostasis in-
volved in self-nonself recognition (11).
' Abbreviations used in this paper: BMT, bone marrow transplantation;
CCE, counterflow centrifugation elutriation; CsA, cyclosporine;
GVHD, graft-versus-host disease; R/O, rotor-off; SGVHD, syngeneic
GVHD.
This autoimmune disease, which occurs 14-21 d afterces-
sation of CsA therapy, is mediated by T lymphocytes (6, 7)
and is intimately associated with the appearance of OX8+
(CD8) autocytotoxic T cells that recognize a public epitope
on class II major histocompatibility antigens (8). A W3/25+
(CD4) Th cell subset also plays an essential role in disease
manifestation (7). Further studies have suggested that a T
lymphocyte-dependent host resistance mechanism must be
eliminated before the development of this autoaggression syn-
drome can occur (11, 12). Of additional importance are the
recent findings that indicate that in addition to thymic ir-
radiation and CsA treatment, age is a critical variable for the
induction of SGVHD (13); animals >3 mo of age are much
more resistant to the induction of autoimmunity with CsA.
The mechanism accounting for the resistance of mature animals
is unknown, but it may be related to the lack ofa pronounced
effect of CsA on the thymic medulla, as postulated by
Beschorner et al. (14). On the other hand, recent evidence
suggests that there are increased numbers ofautoregulatory
cells in older animals, thus preventing the clonal amplification
of autoreactive cells (13).
In the present study, we demonstrate that there is a
significant correlation of age with the induction of SGVHD;
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ofageat the time oftransplant, thereafter, theincidencerap-
idly decreases with age. Surprisingly, the age of themarrow
donor was a much more critical variable for the induction
of SGVHD than the age of the recipient. Furthermore, evi-
dence is provided that theinability to induce SGVHD when
using marrow from donors >3 mo of age is due to marrow-
derived mature T lymphocytes. Addition of theseT cells to
marrow from animals 1 mo of age inhibited the induction
of SGVHD.
Materials and Methods
Rats.
￿
Lewis female (RT') rats, which were corona virus free
and 1, 3, or 6 mo of age, or neonatally thymectomized Lewis fe-
male rats, were purchasedfrom Charles RiverBreeding Laborato-
ries, (Wilmington, MA) and kept in sterile microisolator cages.
TotalBody Irradiation.
￿
Lewisrats were irradiated on day -1 with
1,050 rads at 108 rads/min from a dual source is7Cs small animal
irradiator (Atomic Energy of Canada Ltd., Kanata, Ontario,
Canada).
Bone Marrow Transplantation.
￿
Donor viral-free Lewisrats were
killed by C02 asphyxiation. Marrow was collected from the
femurs, tibia, and humeri in RPMI 1640. Themarrow cells were
adjusted to a concentration of 6 x 10' nucleatedcells/ml, andwere
infused into recipient animals by intravenous injectioninto thedorsal
tail vein on day 0. The total volume injected was 1 ml.
Antibiotics. Rats received medicated drinking water sup-
plemented with bactrim, neomycin, and polymyxin B, as previ-
ously described (6).
CsA.
￿
CsA was the generous gift of Sandoz Ltd., Basel, Swit-
zerland. Thepowdered CsAwasdissolvedin 95%ethanol andadded
to a 5% Emulphor solution in deionized Ha0. Rats were weighed
daily and received 1 ml/100 g subcutaneously from the day of
marrow infusion for 30 consecutive days. The total dose of CsA
per dayper rat waseither 15, 10, 5, or 1 mg/kg. Control animals
received the identical quantities of thedrug diluent (ethanol, 5%
emulphor, HZO) without CsA.
Assessment ofSGVHD
￿
Rats were examined daily for signs of
clinical GVHD. Ear biopsies were taken at frequent intervals. Ini-
tial onsetof SGVHDoccurred within 7-14 d after discontinuation
of CsA therapy and was presented as an acute GVHD with ery-
thema and dermatitis (9). Within 2 wk after onset, the disease
progressed to a more chronic type of GVHD with alopecia and
fibrosis (9). Animals were followed 6-8 wk after discontinuation
ofCsAtherapy to assess either a delayed appearance ofdisease, reso-
lution ofdisease, or progression and development ofextensivedis-
ease. Upon thedevelopment of chronic disease, the animals were
killed. Previously described criteria were used for histologic
documentation ofGVHD (15). Acute SGVHDwasdefined by the
presence of dyskeratotic cells and vacuolar degeneration lympho-
cytic exocytosis, epidermal destruction with vascular changes of
the basal layer, dyskeratotic cells, and lymphocytec dermal, and/or
epidermal infiltration. Animals with extensive diseasewere killed
and autopsies were performed. The skin, tongue, liver, intestine,
andspleen were histologically examined for thepresence ofGVHD.
Histological examination anddiagnosis ofSGVHDwere performed
by an observer blinded to experimental protocol.
Cell Separation.
￿
Counterflow centrifugation elutriation wasused
to separate bone marrow cells on thebasis ofcell size anddensity.
As previously described (16), this technique allows the separation
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ofrelatively distinct cell populations and enriches forthelympho-
cytes contained in marrow.
Briefly, 0.4-1 x 10' bone marrow cells suspended in 5-10 ml
of elutriation medium (0.9% saline, 0.5% BSA, 0.3 mM EDTA,
pH 7.20) were injected into theinlet stream leading into theJ6M
centrifuge equipped with a JE-6B elutriator rotor and standard
chamber (Beckman Instruments, Palo Alto, CA). The cells were
loaded into the chamberat aflow rate of 15 ml/min, arotor speed
of 3,000 RPM (900 g), and a temperature of 18°C. Rotor speed
was held constant and the cells were eluted by changing the flow
rate. In thecase of ratbone marrow (17), lymphocytes were purged
at a flow rate of25 ml/min (400-mlcollection), andintermediate
sizedcellsat 29 ml/min (200 ml).Cellsstillremainingin theelutri-
ator chamberwere collected by continuing medium flow afterstop-
ping the rotor, and were designated the rotor-off (R/0) fraction.
The cells were then washed and resuspended in RPMI 1640.
mAh
￿
Murine antibodies directed against rat lymphocyte de-
terminants were purchased from Serotec Bioproducts for Science,
Inc. (Indianapolis, IN). The specific mAb from ascites fluid used
in our studies consisted of OX19 (panspecific for rat T lympho-
cytes), W3/25 (specific for rat Th cells), OX8 (identifies the rat
nonTh cell subset), OX7, (detects theThy-1.1 antigen), andOX33
(specific for the K L chain).
Immunomagnetic Separation.
￿
Bone marrow cells from normal
animalswere first separatedby counterflow centrifugation elutria-
tion (CCE) and then depleted of specific subsets by immunologic
separation usingimmunomagnetic beadscoated commercially with
covalently bound, affinity-purified (Fc-specific)sheeppolyclonal Ig
against mouseIgG1 subclass (Dynabeads;DynalInc., GreatNeck,
NY) as previously described (12). Briefly, 5 x 10' cells were in-
cubated with saturating concentrations of primary antibody for
30 min at 4°C. At the endof theincubation, thesupernatant was
removedandthecellswere thoroughly washed with PBSand0.5%
BSA three times. The cells were then incubated with the micro-
spheres (one cell/five beads) for 30 min at 4°C on a hematology
mixer. To remove theunboundcellsfrom the suspension, thetube
was held near a magnetic particle concentrator (P & S Biochem-
ical, Inc., Gaithersburg, MD) for afewminutes, andthen thenonad-
herent population was removed with a Pasteur pipet. The posi-
tively selected cells were complexed to themicrospheres localized
by the magnetic fluid.
Flow MicroJiuorimetry Analysis.
￿
After each type of cell separa-
tion listed above, the depleted populations were stained with an
FITC conjugate o£ the primary antibody used for depletion, an
FITC conjugateofthemAbto thereciprocal subset, or an isotype-
specific FITC sheep anti-mouse IgG to detect residual cells coated
with the primary antibody used in selection. The single im-
munofluorescence was analyzed on aFACScan analytical scanner
(Hewlett-Packard Co., No Alto, CA). Thenegatively selected popu-
lationswere less than 5% contaminatedby thedepleted cell subset
on average.
StatisticalAnalysis.
￿
Results were analyzed by multivariate anal-
ysis or by the Xa test.
Results
TheEffect ofAgeon theInductionofSGVHD
￿
Initialstudies
were undertaken to assess the effect of age on the induction
of SGVHD in Lewis rats treated with C&A after syngeneic
marrow transplants. Animals of 1, 3, or 6 mo of age were
irradiated, reconstituted with marrow from similarly aged
Marrow-derived T Lymphocytes in Syngeneic Graft-versus-Host Diseasesyngeneic donors, respectively, and treated with graded doses
of CsA for 30 d. The results in Fig. 1 demonstrate a sig-
nificant effect of age on the induction ofSGVHD. 1-mo-old
transplanted Lewis rats demonstrated a virtual 100% inci-
dence ofSGVHD when treated with 10 and 15 mg ofCSA ;
a 70% incidence was observedwhen the animals were treated
with 5 mg/kg of this drug. In contrast, a moderate incidence
(50%) ofSGVHD was observed in animals that were trans-
planted at 3 mo of age, and only at the highest dose ofCsA
tested . A minimal incidence ofSGVHD was observed in rats
that were initially transplanted at 6 mo of age.
A series of experiments was performed to further analyze
the effect of age on the induction ofSGVHD by separating
marrow donors and recipients on the basis of age. The study
was designed to assess whether donor and/or host age is a
factor that influences the frequency ofSGVHD induced with
CsA . Lewis rats of either 1, 3, or 6 mo of age were used
as donors of bone marrow for lethally irradiated 10-wk-old
recipients . The reciprocal experiment was performed in which
the 1-, 3-, and 6-mo-old Lewis rats served as recipients of
bone marrow from 10-wk-old rats. The recipients were treated
with graded doses ofCsA for 30 d after irradiation and bone
marrow reconstitution . Fig . 2 A illustrates that there was
a significant (p < 2 x 10-4 ) correlation of the age of the
marrow donor with the induction ofSGVHD in 10-wk-old
recipients . The greatest frequency ofSGVHD was observed
in animals grafted withmarrow from rats 1mo of age. Marrow
derived from animals 3 or 6mo ofage resulted in a decreased
incidence of SGVHD. Comparatively, the age of recipient
also correlated (p < 10-3 ) with the ability ofCsA to induce
SGVHD. Theyoungest recipients had the greatest incidence
of SGVHD. The effect of the dose of CsA was more inti-
mately associated with donor age than with recipient age.
However, lowering the doses ofCsA administered in the re-
cipient study (Fig . 2 B) was reflected in a less dramatic de-
cline in incidence.
Additional studies summarized in Fig. 3 further assessed
Figure 1 .
￿
The effect of age on the induction of SGVHD with
graded doses of CSA. Lewis rats of 1, 3, and 6 mo of age were ir-
radiated and grafted with marrow from similarly aged syngeneic rats,
respectively. The recipients were treated with graded doses of C&A
for 30 d, and the incidence ofSGVHD was observed after discon-
tinuation of CsA therapy. (n - 8 per group) .
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Figure 2 .
￿
Separation of donor age from recipient age effects on the
induction of SGVHD. (A) Lewis rats of either 1, 3, or 6 mo of age
were used as bone marrow donors for irradiated syngeneic recipients
that were 10 wk of age. The recipients were treated with graded
doses of C&A for 30 d. (B) Irradiated Lewis rats 1, 3, or 6 mo of age
received bone marrow from 10-wk-old syngeneic donors and treated
with graded doses of CsA for 30 d . The recipients (A and B) were
observed for appearance ofSGVHD after discontinuation of CsA
treatment (n - 10 per group) .
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￿
Combined effects of donor and recipient age on the in-
duction of SGVHD. Lewis rats 1 mo of age were used for donor
marrow for recipients either 1 or 3-6 mo old. Rats 6 mo of age
were used for donor marrow grafts for recipients 1 month or 3-6
months of age. The recipients were treated for 30 d with 15
mg/kg/d of C&A and observed for the appearance of SGVHD after
discontinuation of C&A therapy (n - 8 per group).the combined effects ofdonor and recipient age at a 15 mg/kg
dose of C&A using marrow donors and recipients of either
1 or 3-6 mo of age. The results revealed that the greatest
incidence of SGVHD after CsA therapy occurred when the
marrow was derived from donors 1 mo of age. At this dose
of CsA, SGVHD was induced in 90% ofrats 3-6 mo of age
when the marrow donor was 1 mo old. Taken together with
the results presented in Fig. 2 B, it appears that the recipient
age variable can be overcome by increasing the dose of CsA
and the use of donor marrow derived from younger animals.
In contrast, when marrow is derived from donors that are
>3 mo of age, only a moderate (30%) incidence of SGVHD
occurs after CsA therapy, and it was not enhanced signifi-
cantly by increasing the dose of CsA.
The Effect ofCombining Unfractionated Marrow from Young
and Old Donors on the Incidence ofSyngeneic GVHD The next
series of experiments were designed to address whether mixing
unfractionated marrow from animals 1 and 6 mo of age could
modify the incidence of syngeneic GVHD normally induced
with bone marrow from the youngest donors alone.
Bone marrow from donors 1 or >6 mo of age was trans-
fused at first alone into lethally irradiated 8-9-wk-old re-
cipients. As controls, two different doses, 3 x 107 and 6 x
107 nucleated cells, were used to reconstitute the recipients.
The experimental groups received a total of 6 x 107 bone
marrow cells derived from donors 1 and >6 mo of age mixed
in equal proportion. The recipients received 30 d of CsA
therapy (15 mg/kg/d), and the incidence ofsyngeneic GVHD
was observed. The results are summarized in Table 1. Re-
cipients of bone marrow from donors 1 mo of age demon-
Table 1.
￿
The Effect ofMixing UnfractionatedMarrowfrom Animals
1 and 6 mo ofAge on the Induction of Syngeneic GVHD
Incidence and severity
of SGVHD
Irradiated Lewis recipients (8-9 wk of age) were grafted with syn-
geneic bone marrow derived from syngeneic rats 1 mo of age or
from animals 6 mo old. The marrow was infused singly or after
mixing, and the recipients were treated with a 30-d course of CsA
(15 mg/kg/d). After discontinuation of CsA therapy, the animals
were observed daily for the appearance of SGVHD.
strated severe disease in the entire experimental group by at
least day 28 afterdiscontinuation of CsA therapy. Those that
received 6 x 101 developed a more aggressive disease 3 wk
earlier than those receiving 3 x 10' cells. Notably, recipients
of marrow from donors >6 mo of age did not develop dis-
ease if reconstituted with 3 x 107 cells and only one of eight
rats transfused with 6 x 107 cells developed mild SGVHD.
Recipients of 3 x 107 cells from 1-mo-old donors combined
with 3 x 107 cells from donors >6 mo of age demonstrated
the same timing and incidence of clinical SGVHD as those
receiving marrow from the mature donors alone. In sum-
mary, the transfusion of marrow from more mature animals
influences the potential of bone marrow from immature
animals to induce autoimmunity. The marrow from donors
>6 mo of age contained some population(s) of cells capable
of preventing the induction of syngeneic GVHD in the sec-
ondary recipient.
Identification and Characterization ofthe Cells in Marrow of
Mature Animals that Modify the Induction of SGVHD The
studies described abovedemonstrated that marrow from ma-
ture animals modified the induction ofSGVHDwhen added
to the marrow inoculum from animals 1 mo of age. A series
of experiments was undertaken to identify and characterize
the cell population responsible for this effect. Marrow from
Lewis rats of 1 or 6 mo of age was separated on the basis
of size and density by counterflow centrifugal elutriation,
a technique routinely used to T cell deplete human bone
marrow (16) and recently adapted for use in the rat, allowing
excellent recovery of the cells (17) . Small lymphocytes are
purged at a flow rate of 25 ml/min, larger lymphocytes and
myeloid cells at 29 ml/min, and the clonogenic hemopoietic
and blast cells are collected by stopping the rotor, thus named
the R/O fraction. Initial studies compared the separation char-
acteristics of marrow from 1- and 6-mo Lewis rats. There
was a moderate increase in the number of cells isolated in
fraction 25 of marrow from 1-mo-old animals (44%) com-
pared with marrow from animals 6 mo of age (28%). This
was reflected by differences in yield from the 29 and R/O
fractions (fraction 29, 11% and 16%; R/O fraction, 43%
vs. 53%, respectively).
Studies were performed to assess if a given fraction from
the marrow of donors 6 mo of age was responsible for
preventing the induction of SGVHD. Marrow from Lewis
rats 6 mo of age was elutriated into 25, 29, and R/O frac-
tions, and 4 x 107 cells from each fraction were transfused
with 2 x 107 or 4 x 107 unfractionated bone marrow cells
from 1-mo-old syngeneic donors into lethally irradiated
recipients (8-9 wk of age). The incidence ofSGVHD in the
recipients was recorded after 30 d of CsA therapy with clin-
ical observations and sequential biopsies until the time of au-
topsy. The results are summarized in Table 2. The recipients
receiving unfractionated bone marrow from 1-mo-old donors
alone developed severe clinical SGVHD at each dose. Those
receiving 2 x 107 cells of unfractionated bone marrow from
the immature rats and 4 x 107 cells of unfractionated bone
marrow from donors 6 mo of age developed disease in only
three of eight rats. At the higher dose of bone marrow cells
from donors 1 mo of age, addition of unfractionated bone
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Marrow graft
composition Fraction with
Age of
marrow donor Cell dose
clinical
Day 7
SGVHD
Day 28 Severity
x 10'
6 mo 3 0/6 0/6
6 0/8 1/8 Mild/recovered
1 mo 3 0/8 8/8 Severe/died
6 8/8 8/8 Severe/died
6+Imo 3
3 0/8 1/8 Mild/recoveredTable 2.
￿
TheElectofMixing UnfractionatedMarrowfrom Animals
1 mo ofAge with Elutriated Marrowfrom Animals 6 mo ofAge on
the induction of Syngeneic GVHD
Marrow was harvested from 6-mo-old Lewis rats and fractionated by
elutriation. Unfractionated marrow or the respective 25, 29, R/O
elutriation fractions (4 x 107 cells) were added to marrow derived
from 1-mo-old syngeneic Lewis rats and infused into Lewis rats (8-9
wk of age). As controls, the recipients received either marrow from
rats 1 or 6 mo of age or the elutriation fractions separately. The
recipients were treated with a 30-d course of CsA therapy (15
mg/kg/d) and observed for the onset of SGVHD.
marrow from donors 6 mo of age resulted in five of eight
rats developing SGVHD. However, SGVHD did not occur
in recipients receiving either 2 or 4 x 107 bone marrow cells
from the immature donors and 4 x 107 elutriated bone
marrow cells isolated in fraction 25 from donors 6 mo of
age. Thus, fraction 25 had the most potent inhibitory effect
on the prevention ofsyngeneic GVHD. Addition ofthe R/O
and/or fraction 29 from marrow of 6-mo-old animals to un-
fractionated marrow from donors 1 mo of age did not
significantly influence the induction ofsyngeneic GVHD. Fur-
thermore, animals grafted separately with the R/O fraction
or the 29 fraction from marrow of animals 6 mo of age, en-
grafted and developed SGVHD after a course of CsA (15
mg/kg) therapy. Animals did not engraft when fraction 25
was used singly.
The potent capabilityofunfractionated marrow from donors
6 mo of age to inhibit the primary induction of syngeneic
GVHD with marrow from immature animals appeared to
be isolated in elutriation fraction 25. This fraction also ac-
counted for the inability of marrow from animals 6 mo of
age to allow the induction ofSGVHD. Further studies were
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undertaken to phenotypically characterize the cells contained
in fraction 25 of marrow from both mature (6 mo) and im-
mature (1 mo) Lewis rats. Single-color flow cytometricanal-
ysis demonstrated that fraction 25 from animals 6 mo of age
(mean of three experiments) had a predominance of cells
with mature T lymphocyte markers: 22.6% OX19+, 12.3%
CD4+, and 8.4% CD8+ . (Table 3) . Fraction 25 from 1-mo-
old animals had 12.5% cells with mature T cell markers, and
a predominance of B cells (OX 33+) and cells expressing
OX7 or Thy-1.1 (B cells also express OX7). There was also
a significant percentage ofcells not staining with any markers.
The greatest difference appeared to be the reduced number
of T cells in fraction 25. Comparatively, the marrow R/O
and 29 fractions from both groups had minimal total T cells
defined by staining with OX19 (fraction 29 <15% ; R/O
<5%). Furthermore, fraction 29 is only a small percentage
(11-16%) of the entire elutriated marrow.
Experiments were undertaken to assess if depletion of the
mature T cells or the cells expressing the OX7 marker in
fraction 25 of marrow from mature Lewis rats removed the
ability of this fraction to inhibit induction of SGVHD. Ir-
radiated Lewisrats (8-10 wk ofage) were grafted with marrow
from donors 1 mo of age to which unfractionated marrow,
fraction 25, and fraction 25 depleted of T cells or OX7+ cells
was added (derived from animals 6 mo of age). The recipient
animals were treated with the standard course of CSA (30 d,
15 mg/kg/d), and the incidence of SGVHD was observed
afterwithdrawal ofCsA therapy. The results in Table 4 show
that only depletion of the mature T lymphocytes removed
the inhibitory activity of fraction 25 on the induction of
SGVHD. Further studies showed that depletion ofeither the
W3/25 (CD4) or OX8 (CD8) subsets alone removed the
inhibitory effect on the induction of SGVHD. However,
recombining the fractions restored the inhibitory activity as
reflected by the prevention of SGVHD, indicating that both
subsets were required.
Marrow from Lewis rats 1 mo of age also contained ma-
ture T cells, but yet allowed for induction of SGVHD. We
Table 3.
￿
Phenotypic Analysis ofElutriation Fraction 25from Mar-
row Donors 1 and 6 mo of Age
Donor
￿
1 mo
Age of marrow donor
6 mo
OX 19 (T lymphocytes)
￿
12.5
￿
22.6
CD4
￿
6.3 12.3
CD8
￿
5.2
￿
8.4
OX 33 (B lymphocytes)
￿
30.1
￿
11.8
OX 7 (Thy-1 .1)
￿
71.6
￿
26.1
Marrow derived from immature (1 mo) and mature (6 mo) Lewis
rats was elutriated, and the cells in fraction 25 were assessed for ex-
pression of known phenotypic markers by single-color flow cytomet-
ric analysis. Results are the mean of three separate experiments.
Marrow graft composition
Marrow cell dose Marrow fraction from
from animals animals 6 mo of age
1 mo of age (4 x 10' cells)
Incidence of
SGVHD
(fraction with
clinical SGVHD)
x 10'
4 None 8/8
4 Unfractionated 5/8
4 25 0/8
4 29 5/8
4 R/O 7/8
2 None 8/8
2 Unfractionated 3/8
2 25 0/8
2 29 6/7
2 R/O 6/7
0 Unfractionated 1/8
0 25 Failed to Engraft
0 29 3/4
0 R/O 4/4Table 4.
￿
The Effect of T Cell Depletion of Marrow Fraction 25 from Mature Donors on the Induction ofSGVHD
Marrow was harvested from Lewis rats 6 mo of age and fractionated by elutriation. Fraction 25 or the lymphocyte-enriched fraction was
depleted of 0X7+ cells or T lymphocytes (0X19, 0X8, W3/25 cocktail) with immunomagentic beads. The unfractionated marrow, fraction
25, and/or the depleted fractions were mixed with marrow derived from syngeneic rats 1 mo of age and grafted into irradiated Lewis
recipients (8-10 wk of age). The animals were treated with CsA (15 mg/kg/d, for 30 d) and observed for the onset of SGVHD after discon-
tinuation of therapy.
attempted to assess if the ability of young marrow to allow
induction of SGVHD was due to the decreased number of
mature T cells described above or due to an absence ofspecific
regulatory cells that reside in fraction 25 of marrow from
older animals. A dose-response study was performed in which
graded doses of T lymphocytes in fraction 25 of marrow from
both Lewis rats 1 and 6 mo of age were infused with unfrac-
tionated marrow from 1-mo-old animals into irradiated
recipients (6-8 wk of age). The recipients were treated with
CsA (15 mg/kg/d) for 30 d, and the incidence of SGVHD
was observed. The results in Table 5 demonstrate that addi-
tion of >5 x 106 T cells from fraction 25 of donors 6 mo
of age completely abolished the induction of SGVHD, while
2.5 x 106 T cells reduced the incidence of SGVHD to 50%.
Comparatively, even the addition of 107T lymphocytes of
fraction 25 from the marrow of animals 1 mo of age did not
inhibit the induction of SGVHD. Similarly addition of splenic
(nylon wool-nonadherent) T lymphocytes (:10') from an-
imals 6 mo ofage to the inoculum of marrow, prevented the
development of SGVHD after CsA therapy. On the other
hand, only the highest dose of splenic T lymphocytes from
donors 1 mo of age inhibited the induction of SGVHD.
Role of the Host Resistance Mechanism on the Induction of
SGVHD A series of experiments was undertaken to iden-
tify the role of the host resistance mechanism in preventing
the induction of SGVHD. The results from the studies de-
scribed above indicate that addition of mature T lympho-
cytes from animals 6 mo of age to the marrow inoculum at
Graft composition
the time of transplant prevented the development of SGVHD.
One hypothesis to account for the inhibition of the develop-
ment of SGVHD is that the mature T lymphocytes (con-
tained in marrow or in spleen) expand during CsA therapy
to levels capable of preventing the expression ofthe autoreac-
tive cells generated during therapy. Recent data suggest that
mature T lymphocytes can expand in a thymec- and antigen-
independent environment (18). To assess ifthe mature T lym-
phocytes including the cells responsible for host resistance
clonally expand, thymectomized Lewisrats were grafted with
marrow depleted ofT lymphocytes by elutriation. 2 wk after
transplantation, the recipients were infused with 5 x 106
splenic T lymphocytes (nylon wool-nonadherent cells) and
treated with CsA (10 mg/kg/d) or the control diluent for
30 d. After therapy, the recipients were infused with 3 x 101
effector T lymphocytes from animals with active SGVHD.
The results in Table 6 demonstrate that SGVHD could not
be transferred into the bone marrow-reconstituted, thymec-
tomized recipients grafted with 5 x 106 T lymphocytes.
However, SGVHD couldbe transferred if the recipientswere
treated with CsA. This was not due to the primary induc-
tion of SGVHD, since control thymectomized recipients
treated with CsA did not develop disease, thus confirming
the data of Sorokin et al. (7) . These data suggest that CsA
interferes with the expansion of a T lymphocyte-dependent
host resistance mechanism carried over with mature T lym-
phocytes and could not prevent the adoptive transfer of dis-
ease with 3 x 107 effector cells.
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Age of marrow donors Unfractionated marrow
Fraction of marrow from
animals 6 mo of age
added (4 x 10')
Incidence of SGVHD
(fraction with
clinical SGVHD)
x 107
1 mo 4 - 8/8
3 - 9/9
3 Unfractionated marrow 0/6
3 FR 25 0/8
3 FR 25:0x7 depleted 0/4
3 FR 25 : T cell depleted 4/4
4 FR 25 : CD8 depleted 4/4
4 FR 25 : CD4 depleted 4/4
4 FR 25 : CD8 depleted (2 x 107) +
FR 25 : CD4 depleted (2 x 107) 0/3
6 mo 4 - 0/3Table 5.
￿
Efficacy of T Lymphocytes in Marrow Fraction 25 and
Spleen to Inhibit the Induction of SGVHD
Age of marrow donors
and graft composition
￿
Incidence
of SGVHD
Graded doses of T lymphocytes in fraction 25 of elutriated marrow
and in nylon wool-nonadherent spleen cells derived from Lewis rats
of 1 and 6 mo of age were added to marrow of 1-mo-old syngeneic
animals. The number of T cells was estimated by expression of
OX19 with immunofluorescent staining. The mixture of cells was
infused into irradiated syngeneic Lewis recipients (6-8 wk of age),
and the rats were treated with the standard course of CsA therapy
(15 mg/kg/d, for 30 d). Animals were observed for the onset of
SGVHD after discontinuation of CsA treatment.
Table 6.
￿
Effect of CsA on the Reconstitution of Host Resistance
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We also compared the efficacy of infusing mature splenic
T lymphocytes from animals 6 mo of age, either on the day
of transplantation or the day of withdrawal of CsA therapy
(day 30), and the results are summarized in Table 7. SGVHD
could not be induced if the T lymphocytes were infused on
the day oftransplant. However, development ofSGVHD was
observed despite the infusion of 3 x 107 normal splenic T
lymphocytes (from animals 6 mo of age) on the day of C&A
withdrawal. These data suggested that the frequency of au-
toreactive lymphocytes exceeded the minimum number of
cells that can be regulated by the host resistance mechanism
transferred with 3 x 10' normal T lymphocytes. To assess
if autoreactive cells could be detected in animals receiving
marrow plus mature T lymphocytes at the time of transplant,
a series ofadoptive transfer studies was performed harvesting
cells on the day of CsA withdrawal. Since CsA therapy
prevented the clonal expansion of the host resistance mecha-
nism carried over with mature T cells in the marrow inoculum,
the premise in these experiments was to evaluate the autoreac-
tive potential of the lymphocytes in animals grafted with
marrow and mature T cells before clonal activation (due to
the presence of C&A) and the subsequent transfer into an en-
vironment with a reduced or absent host resistance mecha-
nism. Transfer of splenocytes (5 x 107) from C&Atreated
recipients grafted with marrow plus 10' T lymphocytes
(from animals 6 mo of age) harvested on day 30 into sec-
ondary recipients did not result in adoptive transfer of dis-
ease (0/6). However transfer of spleen cells (5 x 107) from
CsAtreated animals grafted with marrow but in the absence
of T cells resulted in the development of SGVHD in the sec-
ondary recipients (5/6).
Discussion
The immunobiological mechanisms accounting for the in-
duction of SGVHDby administration ofCsA after syngeneic
BMT are indeed complex and remain enigmatic. Central to
by Peripheral T Lymphocytes
Thymectomized Lewis rats were irradiated (1;050 rad) and reconstituted with syngeneic marrow depleted of T lymphocytes by elutriation. 2
wk after transplant, the recipients were infused with 5 x 106 splenic T lymphocytes from rats 6 mo of age, and the animals were treated
with CsA or the control diluent for 30 d. On day 30, 3 x 10' efector cells from animals with active SGVHD were adoptively transferred
into the thymectomized recipients.
Marrow donors
(1 mo of age)
x 10'
4
Source and number
of T cells added
Marrow (6 mo)
-
(fraction with
clinical SGVHD)
4/4
4 Fraction 25 (10') 0/4
4 Fraction 25 (5 x 106) 0/4
4 Fraction 25 (2.5 x 106) 2/4
Marrow (1 mo)
4 Fraction 25 (10') 4/4
4 Fraction 25 (5 x 106) 4/4
4 Fraction 25 (2.5 x 106) 4/4
Spleen (6 mo)
4 3 x 10' 0/4
4 10' 0/4
Spleen (1 mo)
4 3 x 10' 1/4
4 10' 4/4
Marrow
Treatment of thymectomized
T cells
recipients
CsA therapy
(10 mg/kg for 30 d)
Infusion of SGVHD
effector cells (3 x 10')
on day of CsA discontinuation
Incidence
of SGVHD
x 10' x 10,1
R/O (4) 5 + + 4/4
R/O (4) 5 - + 0/4
R/O (4) - + + 4/4
R/O (4) - - + 4/4
R/O (4) 5 + 0/4
R/O (4) 5 - 0/4Table 7.
￿
Effect of TLymphocytes Infused on the Day of Trans-
plant or After CsA Therapy on the induction of SGVHD
Graded doses of splenic T lymphocytes from animals 6 mo of age
were adoptively transferred into bone marrow (derived from animals
1 mo of age)-reconstituted syngeneic Lewis recipients on the day of
transplant or on the last day of a 30-d course of CsA therapy.
this autoaggression syndrome appears to be the enhanced
generation of autoreactive clones that enter the periphery,
and the essential elimination ofa host resistance or autoregula-
tory mechanism that can modify the action of the autoreac-
tive cells (11, 19, 20) . Previous studies have clearly identified
three important elements necessary for the induction of
SGVHD and the resultant imbalance between autoaggres-
sion and autoregulatory suppression. First, CsA is a neces-
sary requirement for the induction of SGVHD since this syn-
drome only occurs in syngeneic BMT recipients treated with
this drug, although rare exceptions have been noted (6, 21).
Second, radiation also appears to play an essential role in ac-
celerating the appearance of disease. Cheney and Sprent (10)
and Glazier et al. (6, 22) reported that normal, nontransplanted
animals treated with CsA do not develop this autoaggres-
sion syndrome even if treated with very high doses of CsA.
This is in contrast to the routine induction of syngeneic
GVHD after whole-body irradiation, syngeneic BMT, and
CsA therapy. Recent data suggest that in the absence ofradi-
ation, CsA must be administered for 6 mo to induce this
autoimmune disease (23). The third essential requirement is
an intact thymus, which must be included in the field of ir-
radiation. As shown by Glazier et al. (22), shielding of the
thymus during total-body irradiation results in the failure
to induce this syndrome. Further evidence for the importance
and pivotal role of an intact thymus was provided by Sorokin
et al. (7). Syngeneic GVHD could not be induced in thymec-
tomized animals but required that an intact thymus be present.
Although CsA treatment, radiation, and an intact thymus
are required for the successful induction of SGVHD, the
present studies have demonstrated that age is also a critical
variable involved in this autoaggression syndrome. Virtually
a 100% incidence ofSGVHD couldbe induced if the animals
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were initially transplanted and treated with CsA beginning
at 4wk of age. Thereafter, the incidence ofSGVHDdecreased
dramatically with the increasing age of the animals. The in-
verse correlation of age with the successful induction of
SGVHD was surprising since in many murine autoimmune
models, increasing age correlates with the onset of disease
(24, 25). An inverse relationship of age with induction of
autoimmunity with CsA mice has recently been reported (13).
Of particular importance in our studies was the finding that
not only was the age of the recipient a significant variable,
but that the age of the marrow donor had an even greater
effect. SGVHDcould be consistently induced in older animals
if the marrow was derived from animals 4 wk of age, but
not if the marrow donors were 6 mo of age or older.
The effect ofthe recipient's age on the induction ofSGVHD
appears in part to be related to the thymic function of ma-
ture animals and its relative resistance to CsA. Beschorner
et al. (14) recently demonstrated a correlation between the
age ofthe recipient receiving both mediastinal radiation and
concomitant CsA therapy and the capacity of the thymus to
regenerate its normal histologic integrity, post-CsA with-
drawal. A prolonged disappearance of the medulla is more
notable in immature rats than those of mature rats. There
is an associated loss of medullary epithelium, Hassall's cor-
puscles, and class II antigen expression. Mature rats have a
more prominent medulla before CsA therapy and hence are
more resistant to thymic involution. Hassall's corpuscles dis-
appear, however, the medulla still has fusiform epithelium,
dendritic cells, and MHC class II antigen expression despite
CsA therapy. It has been postulated that the loss ofthe thymic
medulla and the marked reduction of MHC class II antigen
expression by CsA treatment results in the abrogation ofclonal
deletion mechanisms and the emergence ofself-reactive clones
(8, 10, 19). The relative resistance of the thymic medulla of
mature animals to the effects of CsA (and the subsequent
preservation of clonal deletion mechanisms) may account for
the decreased ability to induce SGVHD in these animals. How-
ever, at present, we cannot exclude that the resistance of ma-
ture animals is, in fact, due to the ability to rapidly regenerate
a thymic-dependent host resistance mechanism (see below).
The most surprising finding of our studies was that the
incidence of SGVHD was significantly associated with the
age ofthe marrow donor and had an even greater effect than
the age of the recipient. In addition, the age of the recipient
became less important if the donor marrow was derived from
the youngest animals. Marrow from animals 6 mo of age
was, to a large extent, incapable ofpermitting the induction
of SGVHD despite the age of the recipient. In contrast,
SGVHD could be consistently induced, even in mature
animals, provided that the marrow was derived from animals
4 wk of age. Furthermore, mixing marrow from donors 1
and 6 mo of age elicited a reduced incidence of SGVHD,
mimicking that obtained with marrow derived from rats
6mo of age. These data implicated a regulatory effect present
in the marrow of mature animals. Further studies demon-
strated that the regulatory effect in the marrow from animals
6 mo of age was due to the presence of small, mature T lym-
Marrow-derived T Lymphocytes in Syngeneic Graft-versus-Host Disease
Transfer of T lymphocytes
Day of No. of cells
transfer transferred
Incidence
of SGVHD
x 107
Day 0: day of transplant 3 0/4
2 0/4
1 0/4
Day 30: discontinuation
of CsA therapy 3 3/4
2 4/4
1 4/4phocytes. Depletion of the T lymphocytes eliminated the
modifying influence ofmarrow derived from mature animals
on the induction of SGVHD when co-infused with marrow
from rats 1 mo of age. In further support of the regulatory
effect of mature T lymphocytes are the findings that: (a) T
cell-depleted marrow from mature animals was able to permit
the development of SGVHD; and (b) addition of splenic T
lymphocytes from 6-mo-old rats to the marrow from animals
1 mo old prevented the induction of SGVHD. In contrast,
although slightly less in number, the mature T lymphocytes
contained in marrow from the immature animals did not pre-
vent the development ofSGVHD. Dose-response studies clearly
suggested that this regulatory activity was absent in marrow
from the immature animals or was present at a very low fre-
quency. Comparatively, some regulatory activity of splenic
T lymphocytes from young animals on the induction of
SGVHD was observed, but only at higher concentrations of
cells. Much lower numbers o£ splenic T lymphocytes from
animals 6 mo of age were required to prevent the induction
of SGVHD. Taken together, these data suggest that this T
cell-dependent regulatory system capable of modifying the
induction of SGVHD develops as the animal matures. Our
data are consistent with the observations of Sakaguchi and
Sakaguchi (13), who demonstrated that administration of C&A
to newborn mice induced pleiomorphic organ-specific autoim-
mune diseases. CsA treatment was also noted to be far more
effective if started on the day of birth rather than the third
to seventh day afterbirth. Not even higher doses or protracted
periods of C&A treatment couldinduce autoimmunity in adult
mice. Sakaguchi and Sakaguchi (13) attributed these effects
to the development of an autoregulatory system that prevented
the amplification and expression of autoregulatory clones. They
also postulated that CsA prevented the development of this
autoregulatory system and that a temporary absence of this
thymic-dependent regulatory system allowed the differentia-
tion/activation of autospecific effector cells.
Some of the early studies clearly implicated the role of a
host resistance mechanism involved in controlling C&Ainduced
SGVHD. The primary evidence included the finding that
SGVHD could only be transferred into irradiated secondary
recipients, not into normal animals, and that CsA treatment
of normal animals did not induce the SGVHD syndrome al-
though adoptive transfer of these spleen cells into irradiated
secondary recipients resulted in the development ofsyngeneic
GVHD(6, 10, 22). Thesefindings suggest that normal animals
possess a radiation-sensitive component that regulates the ac-
tivity of autoreactive cells, thus preventing the development
of autoimmune GVHD. Adoptive transfer studies in our
laboratory provided evidence that an irradiation- and cy-
clophosphamide-sensitive thymic-dependent system played a
major role in the prevention of SGVHD (11, 12). Further-
more, normal splenic T lymphocytes, when cotransferred with
autoimmune effector cells, prevented the development ofsyn-
geneic GVHD in secondary recipients (12). This regulatory
effect of normal splenic T lymphocytes required collabora-
tion between CD4+ and CD8+ T cell subsets, findings com-
parable with the results of the present studies. Of impor-
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tance was the finding that the adoptive transfer of this host
resistance mechanism was dose dependent, requiring twice
the number of splenic T lymphocytes to SGVHD effector
cells. In contrast, the present studies demonstrate that addi-
tion of small numbers ofT lymphocytes to the marrow graft
at the initiation of the induction phase prevented the devel-
opment of SGVHD. The mechanism whereby the T lympho-
cytes from mature animals inhibit the induction of SGVHD
is unclear. One possibility is that the mature T lymphocytes
contained in the marrow graft expand (despite the presence
of CsA) to levels that are able to modify the action of the
autoreactive cells produced during the 30-d course of CsA
therapy. Recent evidence presented by Powrie and Mason (18)
suggest that mature T cells can proliferate in a thymic- and
antigen-independent environment (thymectomized hosts re-
constituted with T cell-depleted marrow). The present studies
demonstrate that thymectomized rats, reconstituted with T
cell-depleted marrow and infused with small numbers of T
lymphocytes were resistant to the adoptive transfer of SGVHD
with effector splenocytes after waiting 30 d to allow expan-
sion of the normal T cells. However, administration of CsA
during this 30-d period prevented the expansion of this host
resistance mechanism, and SGVHD was successfully trans-
ferred, clearly indicating that CsA prevented the expansion
of this host resistancemechanism such that a limited number
of effector cells (3 x 10') were capable of establishing dis-
ease in these animals. Further, infusion of 3 x 107 normal
T lymphocytes on the day of C&A withdrawal failed to pre-
vent development of SGVHD. These data imply that the
number of autoreactive cells generated during CsA therapy
exceeded the capacity of the host resistance mechanism con-
tained in 3 x 107 normal T lymphocytes. On the other
hand, only a minimum number of normal T cells (5 x 106)
were required to be added to the marrow inoculum and in-
fused on the day of transplant, to prevent the development
of SGVHD. Since CsA administration prevented the expan-
sion of the host resistance mechanism, it would seem likely
that the host resistance mechanism contained in the mature
T lymphocyte populationcarried over with the marrow graft
inactivates the autoreactive cells as they are generated during
the course of CsA therapy. This hypothesis is also supported
by the failure to adoptively transfer SGVHD from animals
grafted with marrow plus mature T lymphocytes to irradi-
ated secondary recipients in which the host resistance mech-
anism had been eliminated. If the failure to induce SGVHD
in animals grafted with marrow plus T lymphocytes from
mature animals was due to a delicate balance ofautoreactivity
and host resistance, thus maintaining active control (suppres-
sion) of the autoreactive cells, one would have expected to
be able to transfer disease in an environment of reduced or
absent host resistance, as shown by Cheney and Sprent (10).
Taken together, it seems likely that host resistance mediated
by T lymphocytes from mature animals clonally inactivate
the autoreactive cells. Inactivation or induction ofdonal anergy
is thought to be the major mechanism controlling autoreac-
tive cells that have escaped clonal deletion mechanisms in the
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